Cargando…

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer

Resistance to docetaxel is a major clinical problem in advanced prostate cancer. The overexpression of AXL receptor tyrosine kinase (AXL) has been correlated with chemotherapeutic drug resistance. However, the role of AXL expression in docetaxel resistance in prostate cancer is yet unclear. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Jian-Zhong, Wang, Zeng-Jun, De, Wei, Zheng, Ming, Xu, Wei-Zhang, Wu, Hong-Fei, Armstrong, Alex, Zhu, Jia-Geng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522277/ https://www.ncbi.nlm.nih.gov/pubmed/28455956 http://dx.doi.org/10.18632/oncotarget.17026

Ejemplares similares

Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
por: Qiu, Xiaofu, et al.
Publicado: (2019)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Overcoming docetaxel resistance in prostate cancer: a perspective review
por: Hwang, Clara
Publicado: (2012)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
por: Bae, Song Yi, et al.
Publicado: (2015)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells
por: Montagnani Marelli, Marina, et al.
Publicado: (2023)

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer
por: Al Nakouzi, Nader, et al.
Publicado: (2014)

Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
por: Jeong, Inae, et al.
Publicado: (2019)

Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
por: Mao, Lijun, et al.
Publicado: (2021)

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer
por: Liu, Rui-ji, et al.
Publicado: (2021)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

Overcoming Drug Resistance and Treating Advanced Prostate Cancer
por: Semenas, Julius, et al.
Publicado: (2012)

Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances
por: Movassaghi, Miyad, et al.
Publicado: (2021)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
por: Huang, Yujie, et al.
Publicado: (2022)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
por: Arichi, Naoko, et al.
Publicado: (2015)

Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines
por: Yang, Jian, et al.
Publicado: (2017)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Molecular mechanisms of docetaxel resistance in prostate cancer
por: Sekino, Yohei, et al.
Publicado: (2020)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
por: Bahmad, Hisham F., et al.
Publicado: (2022)

AXL in cancer: a modulator of drug resistance and therapeutic target
por: Tang, Yaoxiang, et al.
Publicado: (2023)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells
por: Han, Shu-Yan, et al.
Publicado: (2017)

PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy
por: Zeng, Jin, et al.
Publicado: (2018)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
por: Lin, Hui-Ming, et al.
Publicado: (2021)

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
por: Wang, Feng, et al.
Publicado: (2019)

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer
por: Armstrong, Cameron M., et al.
Publicado: (2016)

Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells
por: Deng, Leihong, et al.
Publicado: (2019)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
por: Bascetta, Lorenzo, et al.
Publicado: (2017)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells
por: Bansal, Nitu, et al.
Publicado: (2015)

Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer
por: Singh, Santosh Kumar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o1f2s1vp12sjmi04l8cd3e5764